• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Blenrep Combo Accepted for FDA Review in R/R Multiple Myeloma

by | Dec 3, 2024 | Uncategorized

Source: CureToday articles The FDA has accepted a biologics license application for Blenrep plus bortezomib or pomalidomide for patients with relapsed or refractory multiple myeloma. Read More

Blenrep-Based Combo Provides Survival Benefit in Relapsed/Refractory Multiple Myeloma

by | Nov 18, 2024 | Uncategorized

Source: CureToday articles Findings from a phase 3 trial with Blenrep, Velcade and dexamethasone in relapsed/refractory multiple myeloma will be presented at an upcoming conference. Read More

Triplet regimen extends OS in relapsed or refractory multiple myeloma

by | Nov 14, 2024 | Uncategorized

A triplet regimen extended OS compared with the current standard of care for patients with relapsed or refractory multiple myeloma, according to a topline data announcement.Patients with multiple myeloma often become refractory to first-line triplet or quadruplet...

QOL a Crucial Consideration During R/R Myeloma Treatment Decision-Making

by | Nov 12, 2024 | Uncategorized

Source: CureToday articles Patients with relapsed or refractory multiple myeloma should consider quality of life with survival when choosing the most suitable treatment option. Read More

FDA Receives Application Seeking Approval of Darzalex Faspro in Smoldering Myeloma

by | Nov 11, 2024 | Uncategorized

Source: CureToday articles If approved by the FDA, Darzalex Faspro may be the first treatment for smoldering multiple myeloma as compared to treating the disease once it progresses. Read More

KRd56 Versus KRd27 Shows Similar Effectiveness, Safety in R/R Multiple Myeloma

by | Nov 7, 2024 | Uncategorized

Source: CureToday articles In patients with relapsed or refractory multiple myeloma, KRd56 and KRd27 showed similar effectiveness and safety, but other treatment options may be better. Read More
« Older Entries
Next Entries »

Recent Content

  • Molecular profiling and risk stratification in solitary bone plasmacytoma
  • Safety and Efficacy of Bispecific Antibody Treatment in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis of Proportions from Clinical Trials
  • Increased risk of infections in smoldering multiple myeloma: results from the screened iStopMM study
  • Plasmapheresis facilitates soluble BCMA clearance and contributes to reversing primary resistance to anti-BCMA immunotherapy in multiple myeloma
  • Subcutaneous Darzalex Faspro Extends PFS in Smoldering Myeloma
  • A network meta-analysis of randomized clinical trials in lenalidomide-exposed or -refractory multiple myeloma patients
  • Subcutaneous Bortezomib Associated With Reduced Incidence of Peripheral Neuropathy in Multiple Myeloma
  • Multiple Myeloma: Key Insights on Diagnosis and Evolving Treatment Strategies
  • Multiple myeloma associated long non-coding RNA PLUM confers chemoresistance by enhancing PRC2 mediated UPR pathway activation
  • Mobilization of hematopoietic stem cells using G-CSF with or without cyclophosphamide before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma receiving induction therapy with or without daratumumab
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT